155 related articles for article (PubMed ID: 36963600)
21. Clinical Characteristics of Primary Vitreoretinal Lymphoma in an Indian Population.
Mahajan S; Nijhawan R; Rajwanshi A; Karkhur S; Mulkutar S; Dogra M; Lal V; Gupta V; Gupta A
Ocul Immunol Inflamm; 2017 Oct; 25(5):633-638. PubMed ID: 27003620
[TBL] [Abstract][Full Text] [Related]
22. Intravitreal rituximab monotherapy for management of eyes with vitreoretinal lymphoma: initial experience from India.
Rishi P; Manchegowda PT; Gondhale HP; Rishi E; Das K; Krishnakumar S; Raja T; Biswas J
Int Ophthalmol; 2021 Jul; 41(7):2495-2504. PubMed ID: 33730314
[TBL] [Abstract][Full Text] [Related]
23. Ocular Manifestations of Leukemia and Results of Treatment with Intravitreal Methotrexate.
Vishnevskia-Dai V; Sella King S; Lekach R; Fabian ID; Zloto O
Sci Rep; 2020 Feb; 10(1):1994. PubMed ID: 32029770
[TBL] [Abstract][Full Text] [Related]
24. Effect of intravitreal methotrexate and rituximab on interleukin-10 levels in aqueous humor of treated eyes with vitreoretinal lymphoma.
Raja H; Snyder MR; Johnston PB; O'Neill BP; Caraballo JN; Balsanek JG; Peters BE; Decker PA; Pulido JS
PLoS One; 2013; 8(6):e65627. PubMed ID: 23750271
[TBL] [Abstract][Full Text] [Related]
25. Intraocular chemotherapy for vitreoretinal lymphoma: A review.
Kvopka M; Lake SR; Smith JR
Clin Exp Ophthalmol; 2020 Mar; 48(2):240-248. PubMed ID: 31680408
[TBL] [Abstract][Full Text] [Related]
26. Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse.
Klimova A; Heissigerova J; Rihova E; Brichova M; Pytlik R; Spicka I; Mrazova K; Karolova J; Svozilkova P
Br J Ophthalmol; 2018 Nov; 102(11):1579-1585. PubMed ID: 29378728
[TBL] [Abstract][Full Text] [Related]
27. Retinal and Choroidal Changes of Vitreoretinal Lymphoma from Active to Remission Phase after Intravitreal Rituximab.
Cicinelli MV; Marchese A; Miserocchi E; Giuffré C; Berchicci L; Querques G; Bandello F; Modorati GM
Ocul Immunol Inflamm; 2020 May; 28(4):637-646. PubMed ID: 31393199
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis and management of vitreoretinal lymphoma: present and future treatment perspectives.
Kaburaki T; Taoka K
Jpn J Ophthalmol; 2023 Jul; 67(4):363-381. PubMed ID: 37209195
[TBL] [Abstract][Full Text] [Related]
29. Clinical Experience in a Large Cohort of Patients with Vitreoretinal Lymphoma in a Single Center.
Giuffrè C; Cicinelli MV; Marchese A; Modorati GM; Brambati M; Ferreri AJM; Calimeri T; Ponzoni M; Bandello F; Miserocchi E
Ocul Immunol Inflamm; 2021 Apr; 29(3):472-478. PubMed ID: 32845738
[No Abstract] [Full Text] [Related]
30. Outcomes of intravitreal methotrexate to salvage eyes with relapsed primary intraocular lymphoma.
Mohammad M; Andrews RM; Plowman PN; Hay G; Arora AK; Cohen VML; Sagoo MS
Br J Ophthalmol; 2022 Jan; 106(1):135-140. PubMed ID: 33087316
[TBL] [Abstract][Full Text] [Related]
31. Eyewash with balanced salt solution after intravitreal methotrexate injection in a case of vitreoretinal lymphoma: a simple but effective way to prevent ocular surface toxicity.
Moharana B; Parija S; Palanisamy S; Mishra P
BMJ Case Rep; 2023 Jul; 16(7):. PubMed ID: 37474142
[TBL] [Abstract][Full Text] [Related]
32. Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.
Castellino A; Pulido JS; Johnston PB; Ristow KM; Nora Bennani N; Inwards DJ; Macon WR; Micallef INM; King RL; Salomao DR; Witzig TE; Habermann TM; Nowakowski GS
Am J Hematol; 2019 Mar; 94(3):291-298. PubMed ID: 30516868
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results.
Shields CL; Manjandavida FP; Arepalli S; Kaliki S; Lally SE; Shields JA
JAMA Ophthalmol; 2014 Mar; 132(3):319-25. PubMed ID: 24407202
[TBL] [Abstract][Full Text] [Related]
34. Presentation, Diagnostic Testing and Initial Treatment of Vitreoretinal Lymphoma.
International Vitreoretinal B-Cell Lymphoma Registry Investigator Group
Ophthalmol Retina; 2024 Jan; 8(1):72-80. PubMed ID: 37648063
[TBL] [Abstract][Full Text] [Related]
35. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma.
Larkin KL; Saboo US; Comer GM; Forooghian F; Mackensen F; Merrill P; Sen HN; Singh A; Essex RW; Lake S; Lim LL; Vasconcelos-Santos DV; Foster CS; Wilson DJ; Smith JR
Br J Ophthalmol; 2014 Jan; 98(1):99-103. PubMed ID: 24158837
[TBL] [Abstract][Full Text] [Related]
36. Recurrent pseudohypopyon in association with primary vitreoretinal lymphoma: a case report.
Kitao M; Hashida N; Nishida K
BMC Ophthalmol; 2016 Jul; 16():103. PubMed ID: 27391815
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma.
Fishburne BC; Wilson DJ; Rosenbaum JT; Neuwelt EA
Arch Ophthalmol; 1997 Sep; 115(9):1152-6. PubMed ID: 9298056
[TBL] [Abstract][Full Text] [Related]
38. Potential Diagnosis of Vitreoretinal Lymphoma by Detection of MYD88 Mutation in Aqueous Humor With Ultrasensitive Droplet Digital Polymerase Chain Reaction.
Hiemcke-Jiwa LS; Ten Dam-van Loon NH; Leguit RJ; Nierkens S; Ossewaarde-van Norel J; de Boer JH; Roholl FF; de Weger RA; Huibers MMH; de Groot-Mijnes JDF; Kuiper JJW
JAMA Ophthalmol; 2018 Oct; 136(10):1098-1104. PubMed ID: 30027272
[TBL] [Abstract][Full Text] [Related]
39. Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behcet disease.
Bae JH; Lee SC
Retina; 2012 Jul; 32(7):1395-402. PubMed ID: 22012204
[TBL] [Abstract][Full Text] [Related]
40. Curious case of bilateral non-resolving vitritis - Unmasking the masquerade on ultra-widefield imaging.
Delhiwala K
Indian J Ophthalmol; 2022 Apr; 70(4):1438-1439. PubMed ID: 35326082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
